Palverafusp alfa  (Synonyms: IMM-2510; SYN-2510)

Palverafusp alfa (IMM-2510; SYN-2510) is a PD-L1/VEGF-targeting IgG1κ type humanized antibody. Palverafusp alfa blocks PD-1/PD-L1 binding, relieves immune suppression, mediates PD-L1-directed antibody-dependent cellular cytotoxicity (ADCC). Palverafusp alfa blocks VEGF/VEGFR binding, inhibits angiogenic signaling, relieves VEGF-induced immune suppression. Palverafusp alfa reduces endothelial cell proliferation, enhances ADCC and antibody-dependent cellular phagocytosis (ADCP), inhibits tumor growth, reverses T cell immune suppression. Palverafusp alfa exhibits immune stimulatory, antiangiogenic, and anti-tumor activity in the tumor microenvironment. Palverafusp alfa can be used for the research of cancer, such as solid tumors, non-small cell lung cancer^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

VEGFA/PD-L1^[1]

Palverafusp alfa binds to PD-L1-expressing cell lines and human PBMCs, blocks PD-L1/PD-1 ligand-receptor interactions, and exhibits cooperative binding^[1].
Palverafusp alfa inhibits VEGF/VEGFR signaling and reduces HUVEC proliferation to block angiogenesis^[1].
Palverafusp alfa functionally inhibits T cell immune suppression in Jurkat-PD-1 reporter assays with Raji-PD-L1 cells, with VEGF-enhanced anti-PD-L1 function^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

169.11 kDa

2850355-87-0

Liquid

Colorless to light yellow

[Palverafusp alfa]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa-[PROTEIN]2-in-VH

• 
  Loaded Palverafusp alfa on AHC2 biosensor, can bind VEGF121 Protein, Human (HEK293, His, HY-P70519) with an affinity constant of 2.310E-10 M as determined in BLI assay.

• [1]. Li S, et al. 715 IMM-2510, a novel bispecific antibody targeting PD-L1 and VEGF, exhibits cooperative binding, ADCC activity, and enhanced anti-tumor efficacy, with best-in-class potential[J]. 2025.